Delgocitinib is a topical JAK inhibitor that non-selectively inhibits JAK1, JAK2, JAK3 and TYK2.It blocks the signaling of multiple pro-inflammatory cytokines involved in the pathogenesis of inflammatory skin diseases.
Approved Indications
Atopic dermatitis (eczema) in adults and adolescents
Key Features
Topical formulation (ointment)
Local anti-inflammatory action
Targets multiple cytokine pathways
Suitable for chronic inflammatory skin conditions
Applications
API, intermediates, reference standards for R&D, generic registration and commercial manufacturing.
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
China [CN] 
Click enlarge Image